| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
																	Protagonist Therapeutics to replace Encore Wire in the S&P SmallCap 600 effective prior to the opening of trading on Wedne...
																	The company expects total capital expenditures to range from $130 - $150 million in 2024, $130 - $150 million in 2025, and $100...
																	Encore Wire (NASDAQ:WIRE) reported quarterly earnings of $3.92 per share which beat the analyst consensus estimate of $3.65 by ...
																	CJS Securities analyst Christopher Moore downgrades Encore Wire (NASDAQ:WIRE) from Market Outperform to Market Perform.
																	Sidoti & Co. analyst Julio Romero downgrades Encore Wire (NASDAQ:WIRE) from Buy to Neutral and announces $290 price target.
																	DA Davidson analyst Brent Thielman downgrades Encore Wire (NASDAQ:WIRE) from Buy to Neutral and maintains $295 price target.
																	Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new d...
																	
																	U.S. stocks were higher, with the Dow Jones index gaining over 100 points on Monday. Shares of M&T Bank Corporation (NYSE...